A 12-months Phase 2b trial of PrimeC from Israel’s NeuroSense (see here previously) showed a 73% improvement over placebo in slowing ALS progression among patients. It also achieved a 63% increase in survival rates.
https://finance.yahoo.com/news/neurosenses-paradigm-als-clinical-trial-132700722.html